# Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

> **NCT04553939** · PHASE2 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 50 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04553939
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2023-04-12
- **Final completion:** 2025-04-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553939, "Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04553939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*